Novogen Receives Royalty Payment, Settles Lawsuit

February 28, 2005

1 Min Read
SupplySide Supplement Journal logo in a gray background | SupplySide Supplement Journal


Novogen Receives Royalty Payment, Settles Lawsuit

STAMFORD, Conn.--Novogen Ltd. received a milestone royalty payment of $863,000 under a license agreement with Solae LLC, covering use of patent applications for Novogen soy isoflavone technology. The Solae license relates to Novogen patents or patent applications relating to soy applications.

In additional news, Novogen announced it settled, for an undisclosed amount and terms, the legal action it had taken against General Nutrition Corp. (GNC), alleging patent infringement by GNC on a Novogen patent related to red clover isoflavones for treatment of menopausal symptoms. In addition to the monetary settlement, GNC will reintroduce Novogen's Promensil red clover product through its retail outlets in the United States.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like